A clinical trial for validating therapeutic efficacy of convalescent plasma in severe COVID-19 disease

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Raychaudhuri D, Bandopadhyay P, D'Rozario R, Sarif J, Ray Y, Paul SR, Singh P, Chaudhuri K, Bhaduri R, Pandey R, Bhattacharya P, Sengupta S, Chatterjee S, Ganguly D.

2022-09-144 citations

10.1016/j.mayocpiqo.2022.09.001

A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19.

Ray Y, Paul SR, Bandopadhyay P, D'Rozario R, Sarif J, Raychaudhuri D, Bhowmik D, Lahiri A, Vasudevan JS, Maurya R, Kanakan A, Sharma S, Kumar M, Singh P, Roy R, Chaudhury K, Maiti R, Bagchi S, Maiti A, Perwez MM, Mondal A, Tewari A, Mandal S, Roy A, Saha M, Biswas D, Maiti C, Bhaduri R, Chakraborty S, Sarkar BS, Haldar A, Saha B, Sengupta S, Pandey R, Chatterjee S, Bhattacharya P, Paul S, Ganguly D.

2022-01-1941 citations

10.1038/s41467-022-28064-7

Nature and Dimensions of Systemic Hyperinflammation and its Attenuation by Convalescent Plasma in Severe COVID-19

Purbita Bandopadhyay, Ranit D’Rozario, Abhishake Lahiri, Jafar Sarif, Yogiraj Ray et al. (25 authors)

The Journal of Infectious Diseases2021-01-1298 citations

10.1093/infdis/jiab010

Interventions

Intervention1: Passive Immunization using Convalescent Plasma in COVID-19: Blood group matched convalescent Plasma (COVID Plasma) from recovered COVID-19 patients will be transfused to patients with s

Eligibility

Inclusion criteria

Inclusion criteria: Patients admitted with RNA PCR proven COVID-19 with severe disease (fever or suspected respiratory infection, plus one of the following; respiratory rate >30 breaths/min, severe respiratory distress, SpO2 with Mild ARDS (200 mmHg =5 cm H2O, or non-ventilated) or Moderate ARDS (100 mmHg =5 cm H2O, or non-ventilated) within 5 to 10 days from initial presentation.

Exclusion criteria

Exclusion criteria: 1. Pregnant mothers 2. Patients with age less than 18 years 3. Admitted late after 10 days of initial presentation 4. Patients refusing consent

Design outcomes

Primary

Measure	Time frame
2. To compare â??all causeâ?? mortality 3. To identify the immune correlates for response to plasma therapy. Timepoint: 1. Discharge 2. Discharge/death 3. Day 0, Day 3, Day 7 after admission	—

Secondary

Measure	Time frame
1. To compare recovery from ARDS in both groups 2. To compare time taken to negative viral RNA PCR 3. Adverse reaction to plasma therapyTimepoint: At discharge/death	—

Countries

India

Contacts

Public ContactDipyaman Ganguly

Calcutta School of Tropical Medicine

jaggs.nbmc@gmail.com9830126060

Outcome results

None listed